Navigation Links
Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings
Date:4/1/2013

SAN DIEGO, April 1, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months and the year ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Fourth Quarter 2012 Financial ResultsFor the fourth quarter ended December 31, 2012, Trovagene reported a net loss of $6.3 million, or $0.43 per share, as compared to a net loss of $1.3 million, or $0.12 per share, for the three months ended December 31, 2011. The increase in net loss is primarily due to a change in fair value of derivative instruments related to warrants of $4.9 million, $0.33 per share, as well as an increase in the total research and development costs and general and administrative expenses of $0.7 million, or $0.05 per share, during the fourth quarter of 2012 as compared to the prior year comparable period.

Year End 2012 Financial ResultsFor the year ended December 31, 2012, Trovagene reported a net loss of $11.6 million or $0.89 per share, as compared to a net loss of $2.3 million, or $0.23 per share, for the twelve months ended December 31, 2011. The increase in net loss is primarily due to a change in fair value of derivative instruments related to warrants of $6.7 million, or $0.51 per share, as well as an increase in the total research and development costs and general and administrative expenses of $2.1 million, $0.16 per share, as compared to the prior year comparable period.

Cash and Cash EquivalentsTrovagene had cash and cash equivalents of $10.8 million at December 31, 2012, as compared to $0.7 million at December 31, 2011. The increase in cash is primarily the net result of cash provided by financing activities, including net proceeds of $9.1 million received from an underwritten public offering of our common stock and warrants in the second quarter of 2012. In addition, Trovagene closed a private placement which provided net proceeds of $4.4 million in the fourth quarter of 2012.

Review of 2012 and 2013 Announcements Demonstrate Progress in Development Programs

  • Launched HPV-HR assay, a urine-base molecular human papillomavirus (HPV) test in 2013.
  • Extended planned offering of urine-based oncogene mutation tests to include a test for the detection of a specific p53 mutation and a specific double mutation in the hepatitis B virus in 2013.
  • Expanded clinical collaboration with the University of Texas MD Anderson Cancer Center to include the detection of transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers in 2013 from an initial collaboration for the detection transrenal KRAS mutation in the urine of patients with pancreatic cancer in 2012.
  • Entered into research collaboration with Brazil's Barretos Cancer Hospital to evaluate Trovagene's urine-based HPV assay as a potential Pap smear replacement in 2012.
  • Entered into an agreement with India's Strand Life Sciences to validate and commercialize the HPV assay in India and South Asia in 2012.
  • Granted licenses for NPM1 marker for acute myelogenous leukemia to Quest Diagnostics, Duke University and Genoptix, Inc. in 2012. Received a milestone payment related to the NPM1 patent issuance from Ipsogen, S.A.
  • Strengthened patent portfolio. Received notification of issuance of two U.S. patents in 2012. Trovagene now has 60 issued patents and 47 pending patents.
  • Acquired a CLIA-certified, CAP-approved laboratory in 2012.
  • About Trovagene, Inc.

    Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

    (Financial Information to Follow)

    ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

    Chief Financial OfficerAmy Caterina

    Investor RelationsTrovagene, Inc.Trovagene, Inc.858-952-7594858-952-7593szaniboni@trovagene.comacaterina@trovagene.com 

    Trovagene, Inc. and Subsidiaries

    (A Development Stage Company)

    Selected Financial Information

    Consolidated Condensed Statements of Operations 

    (in thousands, except for per share amounts)Quarter EndedDecember 31, 

    Year Ended
    December 31,2012201120122011Revenues$

    163$

    34$
    450$
    257Operating expenses:Research and development 5943081,920910General and administrative 1,0036033,3792,324Total operating expenses1,5979115,2993,234Loss from operations(1,434)(877)(4,849)(2,977)Other income (expense)4-4(56)Gain on extinguishment of debt---623Change in fair value of derivative instruments - warrants (4,896)(370)(6,721)171Net (loss) and comprehensive  (loss)$

    (6,326)$

    (1,247) 

    $

    (11,566)$
    (2,239)Preferred stock dividend(10)(10)(38)(38)Net loss available to common shareholders$

    (6,336)$

    (1,257) 

    $

    (11,604)$
    (2,277)Basic and diluted net loss per share$

    (0.43) 

    $

    (0.12)$

    (0.89)$
    (0.23)Weighted average shares outstanding - basic and diluted14,71610,63213,0679,712 

    Trovagene, Inc. and Subsidiaries

    (A Development Stage Company)

    Consolidated Condensed Balance Sheet Information

    (in thousands)December 31,2012December 31,2011Cash and cash equivalents$

    10,820$

    700Other assets590316Property and equipment, net25523Total assets$

    11,665$

    1,039Accounts payable, accrued expenses and other liabilities$

    730$

    1,430Derivative financial instruments8,7663,840Stockholders' equity (deficiency)2,169(4,231)Total liabilities and stockholders' equity (deficiency)$

    11,665$

    1,039 

     


    '/>"/>
    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
    2. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
    3. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
    4. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
    5. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
    6. Medical Equipment Suppliers in Good Health - Research Report on Bruker Corporation, Agilent Technologies Inc., General Electric Company, Becton, Dickinson and Co. and Thermo Fisher Scientific Inc.
    7. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    8. New Avenues to Market - Research Report on Isis Pharmaceuticals, Inc., Avon Products, Inc., Elizabeth Arden, Inc., Boyd Gaming Corporation and Ameristar Casinos, Inc.
    9. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
    10. Free Research Report on Laboratory Corp. of America Holdings, Sony Corp., Cyberonics, Inc., Olin Corp. and Deluxe Corp.
    11. Free Research Report on Delta Air Lines, Inc., Johnson & Johnson, Barrick Gold Corp., Exelon Corp. and Cirrus Logic, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/9/2016)... LONDON , Feb. 9, 2016 The ... in 2014, and it is expected to grow with ... types, the glass prefilled syringes segment dominated the global ... --> --> The global ... significant rate, due to increasing geriatric population, increasing demand ...
    (Date:2/9/2016)... , Feb. 9, 2016 The new report "Global Blood Monitoring ... Acuity Business Research & Consulting group reveals that global market for ... million in 2014 and expected to grow to US$ 24,830.1 million ... North America , Europe ... , Middle-East and Africa ...
    (Date:2/9/2016)... 9, 2016  Increasingly, health care professionals are enhancing ... with wireless technology. With the Vios Monitoring System from ... and remotely detect problems before they become serious by ... environments. the United States . ... . --> The Vios Monitoring System ...
    Breaking Medicine Technology:
    (Date:2/9/2016)... ... ... The Journal of Pain Research has published the commentary “ Terminology ... author Dr John F. Peppin says “Terminology matters, yet little attention has been paid ... ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the ...
    (Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com is ... to affordable hearing aids , increase industry transparency, and promote awareness of ... States. , “For the average consumer, the hearing aid industry is esoteric and ...
    (Date:2/9/2016)... ... ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley (Denver, ... 2016, hosted by Four Seasons Resort Maui at Wailea as part of the luxury ... the Maui Photo Expedition workshop will once again consist of on-location shoots, ...
    (Date:2/9/2016)... ... 09, 2016 , ... i2i Systems, an early innovator and developer of population ... the latest KLAS report, Population Health Management 2015: How Far Can Your Vendor Take ... health management (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines ...
    (Date:2/8/2016)... ... , ... CURE Media Group , the nation’s leading digital and print ... Awards event , which will annually honor individuals making heroic contributions in the field ... MM Heroes Awards nomination process is officially open through February 17 for patients, ...
    Breaking Medicine News(10 mins):